Roivant Sciences Ltd reports results for the quarter ended in March - Earnings Summary

Roivant Sciences

30/05/2024 14:32

* Roivant Sciences Ltd  ROIV.OQ  reported a quarterly
adjusted
loss of 19 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -20 cents.  The mean expectation of
nine analysts for the quarter was for a loss of 30 cents per
share. Wall Street expected results to range from -37 cents
to -23 cents per share.
    * Revenue rose 5.7% to $28.93 million from a year ago;
analysts
expected $31.51 million. 
    * Roivant Sciences Ltd's reported EPS for the quarter was a
loss
of 19 cents​.
    * The company reported a quarterly loss of $151.12 million.
    * Roivant Sciences Ltd shares had risen by 1.8% this
quarter and
lost 4.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Roivant Sciences
Ltd is $16.50 
This summary was machine generated from LSEG data May 30 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.30          -0.19          Beat
 Dec. 31 2023      -0.32          -0.30          Beat
 Sep. 30 2023      -0.31          -0.40          Missed
 Jun. 30 2023      -0.30          -0.38          Missed